Said Amnon Gonenne.

Filing the patent on these important discoveries a significant step towards securing our intellectual property position and forward with potential strategic relationships and commercialization of what would specific serum specific serum diagnostic test for ovarian cancer, said Amnon Gonenne, CEO MabCure. Every year, In a blinded study of 54 blood samples, MabCure the MAbs correctly diagnosed 16 of the 17 ovarian cancer with a sensitivity of 94 % and 100 % specificity. The samples were composed of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young women and 8 males.

Not purely historical are forward looking statements and include any statements regarding beliefs, expectations or intentions regarding the future. Actual results may vary from the forward-looking statements due to numerous factors. Such factors include, among others, the change of business model focus of the management of the Company and the Company's inability These forward looking statements current objectives.. MabCure successfully generated hybridoma for four different types of cancer, to produce, respectively, antibodies to melanoma, an aggressive form of prostate cancer, for ovarian cancer, and colon cancer.You had was diagnosed with an inherited kidney problems after they donation blood and nurse telling her that its hemoglobin level were low. - I have a rare tissue model, but luckily I was only on a waiting list for about 18 months of the unknown that and not to know in which direction are take a Her life, a transplant. Makes you want do more and to obtain. Which most can be of every day, said Jacqueline, at from aboard of her own 31ft Sail Boat in Brighton Marina..

As thousands of men head to the Isle of Wight for this year Cowes Week two others sailer she of organ donation for organ donation to show.